An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer

Trial Profile

An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Carlumab (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Janssen Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Planned End Date changed from 1 Nov 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top